Home › Companies › IONIS PHARMACEUTICALS INC. › 2023-2024

IONIS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and IONIS PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
405Asset managers
2,098Fund votes
2024-06-06Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IONIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by IONIS PHARMACEUTICALS INC.

These tallies are IONIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IONIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-06
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Brett P. Monia	120,462,201	2,850,850	157,065	--	10,132,983	Majority: yes
Elect Director: Michael Yang	109,136,314	14,191,316	142,486	--	10,132,983	Majority: yes
Proposal 2: An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as	118,899,475	4,228,901	341,740	--	10,132,983	Majority: yes
Proposal 3: Approval of an amendment of the Ionis Pharmaceuticals, Inc	96,453,407	26,912,642	104,067	--	10,132,983	Majority: yes
Proposal 4: Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year:	129,900,428	3,455,435	247,236	--	0	Majority: yes

This meeting is also recorded here as 2024-06-07; both records come from the same filing, so the date should be checked against it.

Source: IONIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-10 — read the filing on EDGAR.

How asset managers voted at the IONIS PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 405 asset managers that disclosed a IONIS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IONIS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To make an advisory vote on executive compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 118,899,475AGAINST: 4,228,901

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensat”): 118,899,475 for, 4,228,901 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,844,719 outstanding shares: 82% for, 3% against (84% of the company cast a for/against vote).

The 403 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%

FOR: 97.8%AGAINST: 2.1%ABSTAIN: 0.1%NOT VOTED: 0.0%UNKNOWN: 0.0%

Largest asset managers voting on “To make an advisory vote on executive compensation.” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	33,705,765	0	For
T. Rowe Price	26,675,395	0	For
Vanguard	17,808,614	0	For
BlackRock	5,679,648	14,620	For
Wellington	5,419,781	0	For
State Street	4,525,067	7,467	For
Clearbridge Investments, LLC	4,353,081	0	For
Tweedy, Browne Co LLC	3,454,676	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	3,092,500	0	For
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
PICTET ASSET MANAGEMENT SA	2,647,321	0	For
Charles Schwab	2,597,208	0	For
BVF INC/IL	2,428,613	0	For
Waddell & Reed	2,345,343	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,308,078	0	For
ORBIMED ADVISORS LLC	2,013,033	0	For
Legg Mason	1,726,610	0	For
Capital Group	1,678,947	125	For
Deep Track Capital, LP	1,492,451	0	For
ARK ETF Trust	1,385,268	0	For
Invesco	1,367,753	0	For
Jackson National	965,716	0	For
Candriam S.C.A.	0	908,486	Against
Man Group plc	824,080	0	For
BNP Paribas Asset Management Holding S.A.	0	733,334	Against

Showing the 25 largest of 403 asset managers. See all 403 in the interactive database.

2. TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER SUCH PLAN BY 3,300,000 SHARES TO AN AGGREGATE OF 38,500,000 SHARES AND TO PROHIBIT CERTAIN SHARE RECYCLING ON FULL VALUE AWARDS.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST 22%

FOR: 96,453,407AGAINST: 26,912,642

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Approval of an amendment of the Ionis Pharmaceuticals, Inc”): 96,453,407 for, 26,912,642 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,844,719 outstanding shares: 66% for, 18% against (85% of the company cast a for/against vote).

The 101 asset managers below cast 77% of the shares they voted on this item FOR (47,546,009 for, 14,024,680 against).

FOR 77%AGAINST 23%

FOR: 47,546,009 (77.2%)AGAINST: 14,024,680 (22.8%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGAT” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	2,220,781	10,997,740	Against
T. Rowe Price	10,283,039	0	For
TWEEDY, BROWNE FUND INC.	0	2,954,743	Against
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,483,221	659	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	965,716	0	For
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	630,000	0	For
TIAA	387,417	0	For
John Hancock	293,466	0	For
Empower	285,377	0	For
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	219,421	0	For
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	130,027	0	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

3. TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2024 FISCAL YEAR.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 129,900,428AGAINST: 3,455,435

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year:”): 129,900,428 for, 3,455,435 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,844,719 outstanding shares: 89% for, 2% against (91% of the company cast a for/against vote).

The 101 asset managers below cast 99.6% of the shares they voted on this item FOR (61,313,861 for, 240,780 against).

FOR 99.5%

FOR: 61,313,861 (99.6%)AGAINST: 240,780 (0.4%)ABSTAIN: 11,637 (0.0%)

Largest asset managers voting on “TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2024 FISCAL YEA” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	13,218,521	0	For
T. Rowe Price	10,283,039	0	For
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,481,345	2,535	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	965,716	0	For
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	630,000	0	For
TIAA	387,417	0	For
John Hancock	293,466	0	For
Empower	285,377	0	For
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	0	219,421	Against
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	130,027	0	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

4. Election of Directors: Brett P. Monia

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 120,462,201AGAINST: 2,850,850

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Brett P. Monia”): 120,462,201 for, 2,850,850 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,844,719 outstanding shares: 83% for, 2% against (85% of the company cast a for/against vote).

The 100 asset managers below cast 99.7% of the shares they voted on this item FOR (61,404,012 for, 161,530 against).

FOR 99.7%

FOR: 61,404,012 (99.7%)AGAINST: 161,530 (0.3%)ABSTAIN: 635 (0.0%)

Largest asset managers voting on “Election of Directors: Brett P. Monia” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	13,218,521	0	For
T. Rowe Price	10,283,039	0	For
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,477,809	6,071	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	849,000	116,716	For
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	630,000	0	For
TIAA	387,417	0	For
John Hancock	293,466	0	For
Empower	285,377	0	For
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	219,421	0	For
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	130,027	0	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 100 asset managers. See all 100 in the interactive database.

5. Election of Directors: Michael Yang

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 109,136,314AGAINST: 14,191,316

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael Yang”): 109,136,314 for, 14,191,316 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 145,844,719 outstanding shares: 75% for, 10% against (85% of the company cast a for/against vote).

The 100 asset managers below cast 85% of the shares they voted on this item FOR (52,109,958 for, 9,455,585 against).

FOR 85%AGAINST 15%

FOR: 52,109,958 (84.6%)AGAINST: 9,455,585 (15.4%)ABSTAIN: 635 (0.0%)

Largest asset managers voting on “Election of Directors: Michael Yang” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	13,218,521	0	For
T. Rowe Price	2,687,377	7,595,662	Against
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,483,880	0	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	116,716	849,000	Against
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	0	630,000	Against
TIAA	387,417	0	For
John Hancock	281,280	12,186	For
Empower	12,077	273,300	Against
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	219,421	0	For
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	73,127	56,900	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 100 asset managers. See all 100 in the interactive database.

6. Amend Omnibus Stock Plan

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (452,549 for, 0 against).

FOR: 452,549 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Eversept Partners, LP	331,849	For
SECTOR GAMMA AS	120,664	For
Warren Street Wealth Advisors, LLC	36	For

7. Amend Stock Compensation Plan

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (600 for, 0 against).

FOR: 600 (100.0%)

Largest asset managers voting on “Amend Stock Compensation Plan” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
GRIMES & COMPANY, INC.	500	0	0	0	For
ZIMMERMANN INVESTMENT MANAGEMENT & PLANNING LLC	100	0	0	0	For

Largest IONIS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of IONIS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 145,844,719 shares outstanding at the time of that meeting.

Top IONIS PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Fidelity	23.11%
2	T. Rowe Price	18.29%
3	Vanguard	12.21%
4	BlackRock	3.90%
5	Wellington	3.72%
6	State Street	3.11%
7	Clearbridge Investments, LLC	2.98%
8	Tweedy, Browne Co LLC	2.37%
9	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	2.12%
10	TWEEDY, BROWNE FUND INC.	2.03%

Reported IONIS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

IONIS PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	16.24%	13F
FMR LLC	14.76%	DEF14A
Vanguard Group	11.30%	13F
BlackRock	7.16%	13F
Black Rock, Inc.	6.21%	DEF14A
State Street	2.85%	13F
T. Rowe Price	2.42%	13F
Geode Capital	1.62%	13F
Charles Schwab	0.89%	13F
Morgan Stanley	0.81%	13F

Percentages above are of 145,844,719 shares outstanding, as reported by IONIS PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IONIS PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At IONIS PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 405 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,098 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: IONIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-10.

IONIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.